In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Elizabeth (Nicki) Bush, Executive Director and Global Head of Endpoint Strategy and COA Measurement at OPEN Health Group to discuss the growing complexity of collecting and interpreting patient data. With insights from the recent FDA workshop around Patient-Focused Drug Development (PFFD), the two discuss the importance of integrating measurement science early in the study design, improving data quality while minimizing patient burden, and ensuring patient data is not just gathered, but meaningfully applied in regulatory submissions.
In this episode of TransPerfect LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences sits down with John Reites, Co-Founder and CEO...
Explore how artificial intelligence is rapidly changing the landscape of clinical trials, from discovering new therapies and complex calculations to protocol optimization. Discover how...
Mark Wade interviews Paul O'Donohoe, Senior Director of Product for eCOA and COA at Medidata. They delve into the challenges and opportunities of adopting...
